The HER2-positive revolution isn't coming. It's here.
In Episode 6 of The Breast Friends Podcast, Dr. Jason Mouabbi and Dr. Paolo Tarantino unpack the practice-changing data emerging from ESMO Breast 2026.
From DESTINY-Breast11 and DESTINY-Breast05 to the growing role of HER2DX, ctDNA, MRI-guided treatment adaptation, and chemotherapy-free strategies, this conversation explores a fundamental shift in breast oncology: moving from treating every patient the same to delivering truly personalized care.
Can we safely eliminate carboplatin?
Can biomarkers tell us who needs less treatment?
Is a chemotherapy-free future finally a reality for certain patients?
The future of HER2-positive breast cancer is being written right now.
🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino
▶️ Watch on YouTube - https://youtu.be/WrvmVGEgoIA
🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music
#BreastCancer #HER2Positive #Oncology #OncologyPodcast #ESMOBreast #CancerResearch #ClinicalTrials #PrecisionMedicine #MedicalOncology #MedEd #Enhertu #TDXd